Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.

Luo T, Zhang SG, Zhu LF, Zhang FX, Li W, Zhao K, Wen XX, Yu M, Zhan YQ, Chen H, Ge CH, Gao HY, Wang L, Yang XM, Li CY.

J Exp Clin Cancer Res. 2019 Mar 18;38(1):130. doi: 10.1186/s13046-019-1104-4.

2.

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.

Steinway SN, Dang H, You H, Rountree CB, Ding W.

PLoS One. 2015 May 22;10(5):e0128159. doi: 10.1371/journal.pone.0128159. eCollection 2015.

3.

Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.

Bozkaya G, Korhan P, Cokaklı M, Erdal E, Sağol O, Karademir S, Korch C, Atabey N.

Mol Cancer. 2012 Sep 11;11:64. doi: 10.1186/1476-4598-11-64.

4.

Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.

Gui Y, Yeganeh M, Donates YC, Tobelaim WS, Chababi W, Mayhue M, Yoshimura A, Ramanathan S, Saucier C, Ilangumaran S.

Oncogene. 2015 Nov 12;34(46):5718-28. doi: 10.1038/onc.2015.20. Epub 2015 Mar 2.

PMID:
25728680
5.

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.

Jo JC, Choi EK, Shin JS, Moon JH, Hong SW, Lee HR, Kim SM, Jung SA, Lee DH, Jung SH, Lee SH, Kim JE, Kim KP, Hong YS, Suh YA, Jang SJ, Choi EK, Lee JS, Jin DH, Kim TW.

Mol Cancer Ther. 2015 Nov;14(11):2613-22. doi: 10.1158/1535-7163.MCT-14-0780. Epub 2015 Sep 8.

6.

MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.

Yao Y, Dou C, Lu Z, Zheng X, Liu Q.

Cell Physiol Biochem. 2015;35(3):983-96. doi: 10.1159/000369754. Epub 2015 Feb 2.

7.

Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.

Firtina Karagonlar Z, Koc D, Iscan E, Erdal E, Atabey N.

Cancer Sci. 2016 Apr;107(4):407-16. doi: 10.1111/cas.12891. Epub 2016 Feb 23.

8.

c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

You H, Ding W, Dang H, Jiang Y, Rountree CB.

Hepatology. 2011 Sep 2;54(3):879-89. doi: 10.1002/hep.24450. Epub 2011 Jul 19.

9.

ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.

Ding J, Wen W, Xiang D, Yin P, Liu Y, Liu C, He G, Cheng Z, Yin J, Sheng C, Zhang W, Nan F, Ye W, Zhang X, Wang H.

Oncotarget. 2015 May 10;6(13):11627-39.

10.

Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.

Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS.

PLoS One. 2015 Jan 21;10(1):e0114495. doi: 10.1371/journal.pone.0114495. eCollection 2015.

11.
12.

Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.

Dang H, Steinway SN, Ding W, Rountree CB.

BMC Cancer. 2015 Mar 21;15:161. doi: 10.1186/s12885-015-1166-4.

13.

Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.

Gui Y, Khan MGM, Bobbala D, Dubois C, Ramanathan S, Saucier C, Ilangumaran S.

World J Gastroenterol. 2017 Sep 28;23(36):6639-6649. doi: 10.3748/wjg.v23.i36.6639.

14.

Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase.

Nakanishi K, Fujimoto J, Ueki T, Kishimoto K, Hashimoto-Tamaoki T, Furuyama J, Itoh T, Sasaki Y, Okamoto E.

Clin Exp Metastasis. 1999;17(6):507-14.

PMID:
10763917
15.

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.

Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.

Drug Des Devel Ther. 2015 Aug 26;9:4897-907. doi: 10.2147/DDDT.S85837. eCollection 2015.

16.

MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.

Cheng J, Wu LM, Deng XS, Wu J, Lv Z, Zhao HF, Yang Z, Ni Y.

Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):336-344. doi: 10.1016/j.hbpd.2018.07.006. Epub 2018 Jul 26.

PMID:
30108016
17.

MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.

Korhan P, Erdal E, Atabey N.

Biochem Biophys Res Commun. 2014 Aug 8;450(4):1304-12. doi: 10.1016/j.bbrc.2014.06.142. Epub 2014 Jul 21.

PMID:
25058462
18.

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.

Bladt F, Friese-Hamim M, Ihling C, Wilm C, Blaukat A.

Cancers (Basel). 2014 Aug 19;6(3):1736-52. doi: 10.3390/cancers6031736.

19.

Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.

Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, Zhang L, Shang C, Chen Y.

Clin Cancer Res. 2014 Jun 1;20(11):2959-70. doi: 10.1158/1078-0432.CCR-13-2620. Epub 2014 Apr 3. Erratum in: Clin Cancer Res. 2016 May 1;22(9):2312.

20.

A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.

Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K.

Cancer Biol Ther. 2014 Jun 1;15(6):721-34. doi: 10.4161/cbt.28409. Epub 2014 Mar 11.

Supplemental Content

Support Center